±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Bronchiectasis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå : 1741263
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,279,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,767,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,954,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀåÀº 2025³â 4¾ï 690¸¸ ´Þ·¯, 2032³â¿¡´Â 8¾ï 310¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR)Àº 10.2%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 4¾ï 690¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 10.20% 2032³â °¡Ä¡ ¿¹Ãø 8¾ï 310¸¸ ´Þ·¯

±â°üÁö È®ÀåÁõÀº ÆóÀÇ °ü(±âµµ)ÀÌ ¼Õ»óÀ¸·Î ÀÎÇØ ³Ð¾îÁö°Å³ª ÁÖ¸Ó´Ï ¸ð¾çÀ¸·Î º¯ÇÏ´Â ÁúȯÀÔ´Ï´Ù. ±â°üÁö È®ÀåÁõÀÌ »ý±â¸é ÆóÀÇ Á¡¾×ÀÌ Àß ¹èÃâµÇÁö ¾Ê¾Æ °¨¿°¿¡ ÀÚÁÖ °É¸®°Ô µË´Ï´Ù. °í¸§À̳ª Á¡¾×À» µ¿¹ÝÇÑ ±âħÀÌ ¸¹ÀÌ ³ª¿À´Â °ÍÀÌ ±â°üÁö È®ÀåÁõÀÇ ÁÖ¿ä Áõ»óÀÔ´Ï´Ù. ±â°üÁö È®ÀåÁõÀº ¿ÏÄ¡ÇÒ ¼ö´Â ¾øÁö¸¸ Ä¡·á¸¦ ÅëÇØ °ü¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù.

±â°üÁö È®ÀåÁõ Ä¡·áÁ¦´Â ±â°üÁöÀÇ È®ÀåÀ» Ư¡À¸·Î ÇÏ´Â ¸¸¼º È£Èí±â ÁúȯÀÎ ±â°üÁö È®ÀåÁõÀÇ Áõ»ó°ú ÇÕº´Áõ °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌµé ¾àÁ¦´Â ¸¸¼º ±âħ, °úµµÇÑ Á¡¾× ºÐºñ, Àç¹ß¼º È£Èí±â °¨¿° µîÀÇ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¿½Ã¿¡ Áúº´ÀÇ ÁøÇàÀ» Áö¿¬½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦¿¡´Â ±â°üÁö È®ÀåÁ¦, Á¡¾× Á¦°ÅÁ¦, Ç×»ýÁ¦, Ç׿°ÁõÁ¦ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ȯÀÚÀÇ ¿¹ÈÄ¿Í »îÀÇ ÁúÀ» °³¼±ÇÒ ¼ö ÀÖ´Â »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÖ¾ú½À´Ï´Ù. ±â°üÁö È®ÀåÁõ¿¡ ´ëÇÑ ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸µéÀº »õ·Î¿î Ä¡·á Á¢±Ù¹ý°ú Ç¥Àû ¾à¹°À» °ËÅäÇϰí ÀÖÀ¸¸ç, º¸´Ù È¿°úÀûÀÎ Ä¡·á¿Í ´õ ³ªÀº Áúº´ °ü¸®¿¡ ´ëÇÑ ±â´ë°¨À» ³ôÀ̰í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

±â°üÁö È®ÀåÁõ À¯º´·ü Áõ°¡, Ä¡·á ¿É¼ÇÀÇ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ¿ìÈ£ÀûÀÎ ±ÔÁ¦ ȯ°æ°ú ½ÃÀå ±â¾÷ÀÇ È°¹ßÇÑ R&D Ȱµ¿Àº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 2¿ù »ý¸í°øÇÐ ±â¾÷ Armata Pharmaceuticals, Inc.´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ µÎ ¹øÂ° ÀûÀÀÁõÀÎ ºñ³¶¼º ¼¶À¯Áõ ±â°üÁö È®ÀåÁõ¿¡ ´ëÇÑ ÃÖÀûÈ­µÈ ¸®µå Ä¡·áÁ¦ Èĺ¸¹°Áú AP-PA02ÀÇ ÀÓ»ó½ÃÇèÀ» °³½ÃÇϱâ À§ÇÑ ArmataÀÇ ÀÓ»ó½ÃÇè°èȹ(IND) ½ÅûÀ» ½ÂÀÎÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020³â-2032³â

Á¦6Àå ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â

Á¦7Àå ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â

Á¦8Àå ±â°üÁö È®ÀåÁõ Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¼½¼Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Bronchiectasis Drugs Market is estimated to be valued at USD 406.9 Mn in 2025 and is expected to reach USD 803.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 406.9 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 10.20% 2032 Value Projection: USD 803.1 Mn

Bronchiectasis is a condition where damage causes the tubes in your lungs (airways) to widen or develop pouches. It makes it hard to clear mucus out of your lungs and can cause frequent infections. Coughing a lot with pus and mucus is the main symptom of bronchiectasis. Bronchiectasis can't be cured but can be managed with treatment.

Bronchiectasis drugs are essential for managing the symptoms and complications of bronchiectasis, a chronic respiratory condition characterized by widening of the bronchial tubes. These drugs aim to alleviate symptoms like chronic cough, excessive mucus production, and recurrent respiratory infections while slowing down disease progression. Bronchiectasis drugs encompass bronchodilators, mucus-clearing agents, antibiotics, and anti-inflammatory medicine. Their development has opened new possibilities for improved patient outcomes and quality of life. Ongoing research in bronchiectasis explores novel therapeutic approaches and targeted medications, offering hope for more effective treatments and better disease management.

Market Dynamics:

The increasing prevalence of bronchiectasis, advancements in treatment options, and increasing focus on personalized medicine are anticipated to drive growth of the global bronchiectasis drugs market over the forecast period. Moreover, a supportive regulatory environment and increased research and developmental activities by market players is expected to drive market growth over the forecast period.

For instance, in February 2022, Armata Pharmaceuticals, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application to initiate a clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Bronchiectasis Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

5. Bronchiectasis Drugs Market, By Drug Class, 2020-2032, (US$ Mn)

6. Bronchiectasis Drugs Market, By Route of Administration, 2020-2032, (US$ Mn)

7. Bronchiectasis Drugs Market, By Distribution Channel, 2020-2032, (US$ Mn)

8. Bronchiectasis Drugs Market, By Region, 2020-2032, (US$ Mn)

9. Competitive Landscape

10. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â